08 November 2023
07:29 AM | Europe/Amsterdam
Bayer Group:
Summary
Group sales of 10.342 billion euros (Fx & & portfolio adj. minus 0.2 percent)/ EBITDA before unique products: 1.685 billion euros (minus 31.3 percent)/ Sales steady at Crop Science and Pharmaceuticals and up a little at Consumer Health (Fx & & portfolio adj.)/ Earnings lower at all departments, specifically Crop Science/ Core incomes per share at 0.38 euros (minus 66.4 percent)/ Net earnings at minus 4.569 billion euros, affected by problems losses at Crop Science due to rates of interest/ Free capital at 1.626 billion euros/ CEO Anderson: “We are upgrading Bayer to focus just on what’s necessary for our objective, ‘Health for all, cravings for none'”/ Structural alternatives stay under evaluation